Telomere Parameters in Patients With Nonalcoholic Fatty Liver (telomereFL)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2012 by Meir Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by (Responsible Party):
Meir Medical Center
ClinicalTrials.gov Identifier:
NCT01694342
First received: September 23, 2012
Last updated: September 26, 2012
Last verified: July 2012
  Purpose

Telomerase, through its regulatory function on telomere length may play an important role in immune function, cellular replicative life span, and carcinogenesis. Non-alcoholic fatty liver disease (NAFLD) is considered a benign condition, but in some cases, it may progress to cirrhosis and hepatocellular carcinoma. The risk factors for that evolution are not fully understood.

Our group showed in a previous study, that hTERT mRNA expression is lower in peripheral lymphocytes of patients with fatty liver, compared to healthy controls. This finding could explain the telomere shortening found previously in these patients by our group [20] and others [21]. Furthermore, we found higher rates of TC in these patients, probably due to an attempt to counteract the shortening of the telomeres and to stabilize them. This is through a different mechanism that is not telomerase-mediated.

Telomere capture is considered an alternative way to maintain telomere length and chromosomal stability [3]. It is a more common mechanism for chromosome stabilization and repair, in contrast to the telomerase-mediated process of chromosome healing and elongation This study aimed to evaluate mechanisms of telomere homeostasis like telomere shortening, telomerase activity, telomere capture and aneuploidy in patients with NAFLD in order to explain previous findings of telomere shortening in these patients.


Condition
FATTY LIVER
NO MALIGNANCY
NO DECOMPENSATED ILLNESS

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Telomere Parameters Like Telomere Length, Telomerase Expression, Telomere Capture and Aneuploidy in Patients With Nonalcoholic Fatty Liver

Resource links provided by NLM:


Further study details as provided by Meir Medical Center:

Estimated Enrollment: 30
Study Start Date: September 2012
  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Individuals - over 18 years old that were diagnosed with nonalcoholic fatty liver and are on follow-up in our liver unit

Criteria

Inclusion Criteria:

  • age over 18
  • diagnosis of fatty liver

Exclusion Criteria:

  • no malignancy
  • no eligible to sign the consent paper
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01694342

Contacts
Contact: Yona Kitay-Cohen, MD +97297471560 yonaki@clalit.org.il

Locations
Israel
Meir Hospital Not yet recruiting
Kefar Saba, Israel
Contact: Yona Kitay-Cohen, MD    +97297471560    yonaki@clalit.org.il   
Principal Investigator: Yona Kitay-Cohen, MD         
Sponsors and Collaborators
Meir Medical Center
  More Information

No publications provided

Responsible Party: Meir Medical Center
ClinicalTrials.gov Identifier: NCT01694342     History of Changes
Other Study ID Numbers: ramona 1.0
Study First Received: September 23, 2012
Last Updated: September 26, 2012
Health Authority: Israel: Ethics Commission

Additional relevant MeSH terms:
Neoplasms
Fatty Liver
Liver Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on August 28, 2014